Does AAV-mediated delivery of a CaMKII peptide inhibitor suppress arrhythmias in preclinical models of CPVT?
Gene therapy using AAV-mediated delivery of a CaMKII peptide inhibitor provides proof-of-concept for suppressing arrhythmias in CPVT.
This proof-of-concept study showed that AAV-mediated delivery of a CaMKII peptide inhibitor to the heart was effective in suppressing arrhythmias in a murine model of CPVT. CaMKII inhibition also reversed the arrhythmia phenotype in human CPVT induced pluripotent stem cell-derived cardiomyocyte models with different pathogenic mutations.
Bezzerides et al. (Mon,) studied this question.